Bowel Cancer Worldwide: Survival Hinges on Stage and Where You Live
Published 2026-11-02 · Updated 2026-11-03
Bowel (colorectal) cancer is the third most commonly diagnosed cancer in the world and the second leading cause of cancer death. Where it is found early, most people are alive five years later; where it has spread, or where diagnosis and treatment are out of reach, few are. That gap is the story the data tell.
Behind the global totals are people whose first sign may be a change they put down to something ordinary, families waiting on test results, and health services deciding who to invite for screening, with which test and from what age. Those decisions differ from country to country, and so do the outcomes. This piece sets out what the registries and trials show, says plainly where the evidence is uneven, and draws out what it asks of the services that people with bowel cancer rely on.
Colorectal cancer is the third most common cancer and the second leading cause of cancer death
The most recent global estimates, IARC's GLOBOCAN 2024, published in 2026, put colorectal cancer behind lung and female breast cancer in the number of new diagnoses: 9.9% of the roughly 20.6 million new cancer cases estimated worldwide in 2024. It is second only to lung cancer as a cause of cancer death, accounting for 9.4% of the estimated 9.8 million cancer deaths[1]. The World Health Organization's fact sheet, which draws on the previous edition's estimates for 2022, gives the scale in absolute numbers: an estimated 1.9 million new cases and more than 900,000 deaths worldwide in that year[3].
Where people live changes the picture sharply. An IARC analysis of the 2020 estimates found age-standardised incidence highest in Australia and New Zealand and the European regions, at 40.6 per 100,000 among men, and lowest in several African regions and Southern Asia, at 4.4 per 100,000 among women. Mortality rates were highest in Eastern Europe (20.2 per 100,000 men) and lowest in Southern Asia (2.5 per 100,000 women)[4]. Low recorded incidence in some regions partly reflects where registries are thin, so those figures are estimates, not counts.
Trends point in different directions. WHO notes that incidence and mortality have fallen in several high-income countries, "mainly due to earlier detection"[3]; in the United States, age-adjusted incidence fell by an average of 0.5% a year over 2014 to 2023[5]. The same IARC team projected, from population growth and ageing alone, that annual cases could reach 3.2 million and deaths 1.6 million by 2040, with most cases expected to occur in countries with high or very high human development[4]. That is a demographic projection made in 2022, not a forecast of changing risk.
The exception to the falling trend in high-income countries is younger adults: in the United States, incidence in people under 55 has risen by 1% to 2% a year since the mid-1990s, and the share of colorectal cancers diagnosed before age 55 rose from 11% in 1995 to 20% in 2019[6]. Our study on the rise in cancer under 50 covers that evidence in depth.
Five-year survival ranges from about 70% to under 5%, depending on where a person is diagnosed
The CONCORD-3 programme, which pooled records for 37.5 million people diagnosed with cancer in 2000 to 2014 from 322 population-based registries in 71 countries and territories, found the highest five-year net survival for colon and rectal cancer in South Korea: 71.8% for colon and 71.1% for rectum, for people diagnosed in 2010 to 2014[7].
Even among high-income countries, the gap is wide. The International Cancer Benchmarking Partnership compared seven of them (Australia, Canada, Denmark, Ireland, New Zealand, Norway and the UK) for people diagnosed in 2010 to 2014 and found five-year net survival ranging from 59.1% to 70.9% for colon cancer and from 61.6% to 70.9% for rectal cancer. Survival was "consistently higher in Australia, Canada and Norway", and the differences were largest for colon cancer that had already spread regionally or to distant organs[8].
In parts of the world with fewer diagnostic and treatment services, outcomes are far worse. In Uganda's Kampala Cancer Registry, among 217 people whose colorectal cancer was confirmed by tissue diagnosis between 2000 and 2019, one-year relative survival was 52.7%, three-year 14.5% and five-year 4.3% (95% confidence interval 1.2% to 8.5%)[9]. That is one city's registry and a small number of people rather than a national figure, but it shows how much of the difference in survival lies in access, not in the disease.
| Population | Who was diagnosed, when | Five-year survival | Measure |
|---|---|---|---|
| South Korea (CONCORD-3) | Colon cancer, 2010 to 2014 | 71.8% | Net survival[7] |
| Seven high-income countries (ICBP) | Colon cancer, 2010 to 2014 | 59.1% to 70.9% | Net survival, range across countries[8] |
| United States (SEER 21 registries) | Colorectal cancer, 2016 to 2022 | 65.4% | Relative survival[5] |
| England (national registry) | Bowel cancer, adults 15 to 99, 2018 to 2022 | 59.9% | Net survival, age-standardised[2] |
| Kampala, Uganda (city registry) | Colorectal cancer, tissue-confirmed, 2000 to 2019 | 4.3% | Relative survival[9] |
These figures come from different studies, periods and methods (net and relative survival are close but not identical measures) and are not directly comparable. They show the range of outcomes, not a ranking. Our study on cancer survival around the world explains why the same cancer can have such different survival across countries.
Stage at diagnosis is the single biggest divide in survival
In England, adults diagnosed with bowel cancer at stage 1 between 2018 and 2022 had an age-standardised five-year net survival of 91.6%. At stage 4, when the cancer had spread to distant organs, it was 11.0%: a gap of more than 80 percentage points[2]. The same steep gradient appears in the United States, where five-year relative survival is 91.3% for localised colorectal cancer and 16.9% for distant disease[5].
Yet many people are diagnosed late. In the US registries, only about a third of colorectal cancers (34%) were found at the localised stage in 2016 to 2022; 37% had reached nearby lymph nodes or tissue and 23% had spread to distant organs[5]. National US data show the share diagnosed at an advanced stage rising, from 52% in the mid-2000s to 60% in 2019[6]. In England's survival data, stage 3 or 4 accounted for 47% of the bowel cancers in the analysis, and stage was not recorded for a further 14% (our calculation from the cohort counts in the published data table)[2].
Stage also explains part of the gap between countries. In the ICBP comparison, Canada and Australia, two of the higher-survival countries, had smaller proportions of people diagnosed with metastatic disease, and five-year survival for distant colon cancer ranged from 8.0% to 17.3% across the seven countries[8]. A later stage at diagnosis reflects the gaps in a system: symptoms not recognised, tests not offered, waiting lists, or screening that does not reach everyone. It is not a judgement on the person. Our study on stage at diagnosis and emergency presentation looks at this across cancers.
Screening programmes differ in their test, starting age and positivity threshold
WHO describes screening as having been shown to reduce both the incidence of colorectal cancer and deaths from it[3]. But "bowel screening" means different things in different places. A 2017 review of population programmes found screening under way in most European countries, Canada and parts of the Americas, Asia and Oceania, and identified the faecal immunochemical test (FIT), a home stool test that detects traces of blood, as the most widely used test worldwide[10]. Programmes then differ on who is invited and on the threshold: the amount of blood, in micrograms of haemoglobin per gram of faeces (µg/g), above which a result leads to further tests, usually a colonoscopy. A lower threshold refers more people for further tests, so the choice is a balance between finding more disease and the colonoscopy capacity a service has.
| Country or programme | Test | Age range | FIT threshold |
|---|---|---|---|
| England (NHS) | FIT, every two years | 50 to 74 | 120 µg/g; being lowered to 80 µg/g at early-adopter sites[11] |
| Scotland | FIT | 50 to 74 | 80 µg/g[11] |
| Wales | FIT, every two years | 50 to 74 | 80 µg/g[11] |
| Northern Ireland | FIT | 60 to 74 | 120 µg/g[11] |
| Netherlands | FIT | 55 to 75 (unchanged as of January 2026)[12] | Raised from 15 to 47µg/g after the 2014 launch (as of 2016)[10] |
| Japan (as of 2016) | FIT | 40 to 69 | Not reported[10] |
| Taiwan | Faecal occult blood test (FIT in the 2017 review), every two years | 45 to 74 from January 2025, plus 40 to 44 with a family history; the 2017 review gave 50 to 69[13][10] | Not reported[10] |
| Canada (as of 2016) | Guaiac stool test or FIT | 50 to 74 | Not reported[10] |
| United States (USPSTF recommendation, 2021; no single national programme) | Stool tests or direct visualisation such as colonoscopy | 45 to 75 (grade B for 45 to 49, grade A for 50 to 75) | Not applicable[14] |
Rows marked "as of 2016" are from a 2017 review of programmes and may since have changed; where a current official page was checked, the date is given. The table describes programmes; it is not guidance for any individual.
Starting ages have been moving earlier. In 2021 the US Preventive Services Task Force extended its recommendation to adults aged 45 to 49 (a grade B recommendation), alongside its grade A recommendation for 50 to 75; for 76 to 85 it gives a grade C[14], and Taiwan lowered the starting age of its national programme to 45 in January 2025[13]. Even within the UK, England uses a different threshold from Scotland and Wales. How many people take up the offer varies too, from 68.2% in the Netherlands to 16% in some areas of Canada in the 2017 review[10]; our study on screening uptake covers who is and is not reached.
Trials show what screening can achieve, and that uptake shapes the result
A large randomised trial of colonoscopy screening, NordICC, invited people aged 55 to 64 in Poland, Norway and Sweden to a single screening colonoscopy and compared them with people offered usual care. Among 84,585 participants followed for a median of ten years, and counting everyone invited whether or not they attended (an intention-to-screen analysis), the risk of being diagnosed with colorectal cancer was 0.98% in the invited group and 1.20% in the usual-care group, a risk ratio of 0.82 (95% confidence interval 0.70 to 0.93). The risk of death from colorectal cancer was 0.28% and 0.31% (risk ratio 0.90, 95% confidence interval 0.64 to 1.16), a difference that was not statistically significant[15].
Those results count everyone who was invited, whether or not they attended, and only 42% of the invited group had a colonoscopy[15]. A programme's real-world effect depends on how many people it reaches, which is why participation, follow-up after a positive test and capacity for colonoscopy matter as much as the choice of test. The trial measures the effect of offering one test in one setting; it does not compare colonoscopy with stool-test programmes.
What the evidence asks of us
The figures point to the same few gaps wherever they are measured.
- Diagnose earlier, everywhere. Five-year survival of 91.6% at stage 1 against 11.0% at stage 4 in England[2], and 91.3% against 16.9% in the United States[5], show what is at stake when diagnosis comes late. WHO identifies regular screening as the most effective way to detect colorectal cancer early[3]. Commissioners should treat the share of cancers found at stage 3 and 4 as a measure of the system, not of the people in it.
- Make screening reach people. A programme only works for those it reaches. The NordICC result, with fewer than half of invitees attending, is a reminder that a programme's measured benefit depends on how many people take it up[15]. Funding should follow invitation, reminders, accessible kits and prompt colonoscopy after a positive result.
- Be open about thresholds and ages. Programmes in neighbouring countries invite different age groups and refer at different FIT thresholds[11][10]. Where these are set by colonoscopy capacity rather than evidence, services should say so publicly and plan the capacity to change them.
- Close the global gap. Five-year survival of 4.3% in one Ugandan registry[9], against around 70% in the best-performing countries[7], points to unequal access to diagnosis and treatment. As case numbers are projected to grow worldwide[4], international funders should invest in diagnostic services, treatment and population-based registries in low- and middle-income countries.
- Count better. Stage was missing for 14% of bowel cancers in England's survival analysis[2], and many countries have no population-based registry at all. Better data are how gaps get seen and closed.
More on related evidence is in the Cancer research library.
Language: this piece says "people with cancer" and "people living with and after cancer", and describes the illness and its treatment plainly, without combat metaphors. Clinical terms such as "stage", "incidence" and "net survival" are used in the sense the cited source defines them.
Why we're publishing this
Bowel cancer charities, support groups and hospices make the case every day for earlier diagnosis, fairer screening and better care. This page gathers the core international figures in one place, with each number traced to its source, so that they can be quoted with confidence. The data are on the side of people living with and after bowel cancer and the people who care for them: they show that outcomes depend heavily on when and where someone is diagnosed, and that those are things services can change.
How to read this data
GLOBOCAN figures are modelled estimates for a stated year, built from registry data where they exist and from statistical models where they do not; they are least certain in regions with few registries. Incidence (new cases), mortality (deaths) and survival are different measures and are labelled throughout. Survival figures describe people diagnosed several years ago (for example, 2018 to 2022 in England), so they may not reflect the newest treatments. Net and relative survival both estimate survival from the cancer itself, removing other causes of death, but are calculated differently, and figures from different studies should not be ranked against each other. Stage systems also differ: England reports stages 1 to 4, while the US SEER programme uses localised, regional and distant. Rising survival can partly reflect earlier detection through screening (lead-time), not only longer lives. The screening table describes programmes and recommendations at the dates given; it is not advice about any individual's testing.
Use this data
Free to cite with attribution to Better Health For Everyone. Charities, campaigners and journalists are welcome to reuse these figures and charts. For the underlying figures as a spreadsheet, get in touch.
Important: This article summarises published research for general information. It is not medical advice and cannot be used to diagnose, treat or predict anything about an individual. If you have concerns about your own or someone else's health, please speak to a qualified health professional.
Sources
- Sung H, Filho AM, Laversanne M, Ferlay J, Siegel RL, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA: A Cancer Journal for Clinicians, 2026. europepmc.org/article/MED/42417444
- NHS England Digital. Cancer Survival in England, cancers diagnosed 2018 to 2022, followed up to 2023 (data table 2: survival by stage). NHS England, 2026. digital.nhs.uk/…/cancers-diagnosed-2018-to-2022-followed-up-to-2023
- World Health Organization. Colorectal cancer (fact sheet). WHO, 2026. who.int/news-room/fact-sheets/detail/colorectal-cancer
- Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut, 2023. europepmc.org/article/MED/36604116
- National Cancer Institute. Cancer Stat Facts: Colorectal Cancer. SEER Program, 2026. seer.cancer.gov/statfacts/html/colorect.html
- Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 2023. europepmc.org/article/MED/36856579
- Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3). The Lancet, 2018. europepmc.org/article/MED/29395269
- Araghi M, Arnold M, Rutherford MJ, et al. Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). Gut, 2021. europepmc.org/article/MED/32482683
- Matovu N, Coleman HG, Mutungi G, et al. Colorectal cancer incidence and survival trends in Uganda: a population-based registry analysis (2000-20). International Journal of Epidemiology, 2026. europepmc.org/article/MED/42580674
- Navarro M, Nicolas A, Ferrandez A, Lanas A. Colorectal cancer population screening programs worldwide in 2016: an update. World Journal of Gastroenterology, 2017. europepmc.org/article/PMC/PMC5449420
- Cancer Research UK. Bowel cancer screening (programme details by UK nation). Cancer Research UK, 2025. cancerresearchuk.org/health-professional/cancer-screening/bowel-cancer-screening
- Rijksinstituut voor Volksgezondheid en Milieu (RIVM). Bowel cancer screening programme. RIVM, Netherlands, 2026. rivm.nl/en/bowel-cancer-screening-programme
- National Immigration Agency (Taiwan), Taiwan Immigrants' Global News Network. Notice: Health Promotion Administration expands government-subsidised colorectal cancer screening to ages 45 to 74 from 1 January 2025. Ministry of the Interior, Taiwan, 2025. news.immigration.gov.tw/NewsSection/Detail/f6a48e98-f7f9-4ff4-825d-d3cc83468f20
- US Preventive Services Task Force. Colorectal cancer: screening (final recommendation). USPSTF, 2021. uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening
- Bretthauer M, et al. (NordICC Study Group). Effect of colonoscopy screening on risks of colorectal cancer and related death. New England Journal of Medicine, 2022. europepmc.org/article/MED/36214590
More from this library
- Breast Cancer Worldwide: Where You Live Shapes Who Survives Specific cancers
- Prostate Cancer: Where It Is Found, Where Men Die, and Who Is Most at Risk Specific cancers
- Lung Cancer: The Leading Cause of Cancer Death, Never-Smokers and Stigma Specific cancers
- Pancreatic Cancer: Late Diagnosis, Slow Survival Gains and the Funding Gap Specific cancers
- Blood Cancers: Survival Up for Every Major Type, but Diagnosis Often Comes Late Specific cancers
- Brain Tumours: Rare Overall, a Leading Cause of Cancer Death in the Young Specific cancers